Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.

Curtin NJ, Drew Y, Sharma-Saha S.

Nat Rev Clin Oncol. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2. No abstract available.

PMID:
31582817
2.

Warburg and Krebs and related effects in cancer.

Unterlass JE, Curtin NJ.

Expert Rev Mol Med. 2019 Sep 27;21:e4. doi: 10.1017/erm.2019.4.

PMID:
31558177
3.

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.

Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL.

Cancers (Basel). 2019 Mar 13;11(3). pii: E354. doi: 10.3390/cancers11030354.

4.

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.

Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ.

Biochem Pharmacol. 2019 Sep;167:125-132. doi: 10.1016/j.bcp.2018.10.011. Epub 2018 Oct 17.

PMID:
30342021
5.

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation.

Middleton FK, Pollard JR, Curtin NJ.

Cancers (Basel). 2018 Aug 20;10(8). pii: E275. doi: 10.3390/cancers10080275.

6.

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Franklin M, Gentles L, Matheson E, Bown N, Cross P, Ralte A, Gilkes-Immeson C, Bradbury A, Zanjirband M, Lunec J, Drew Y, O'Donnell R, Curtin NJ.

Cancer Med. 2018 Sep;7(9):4744-4754. doi: 10.1002/cam4.1724. Epub 2018 Aug 14.

7.

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.

Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GL, Allan JM.

Blood Adv. 2018 May 22;2(10):1157-1169. doi: 10.1182/bloodadvances.2017015214.

8.

Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH).

Unterlass JE, Wood RJ, Baslé A, Tucker J, Cano C, Noble MME, Curtin NJ.

Oncotarget. 2017 Nov 6;8(61):104478-104491. doi: 10.18632/oncotarget.22327. eCollection 2017 Nov 28.

9.
10.

Strategies Employed for the Development of PARP Inhibitors.

Canan S, Maegley K, Curtin NJ.

Methods Mol Biol. 2017;1608:271-297. doi: 10.1007/978-1-4939-6993-7_18.

PMID:
28695516
11.

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.

Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ.

NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3736. Epub 2017 May 22.

PMID:
28543772
12.

Targeting the ATR-CHK1 Axis in Cancer Therapy.

Rundle S, Bradbury A, Drew Y, Curtin NJ.

Cancers (Basel). 2017 Apr 27;9(5). pii: E41. doi: 10.3390/cancers9050041. Review.

13.

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.

Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.

14.

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C.

Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26. Review.

15.

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ.

Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4.

16.

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.

Unterlass JE, Baslé A, Blackburn TJ, Tucker J, Cano C, Noble MEM, Curtin NJ.

Oncotarget. 2016 Aug 22;9(17):13139-13153. doi: 10.18632/oncotarget.11487. eCollection 2018 Mar 2.

17.

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity.

O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ.

Int J Gynecol Cancer. 2016 Jul;26(6):1004-1011. doi: 10.1097/IGC.0000000000000745.

PMID:
30814168
18.

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity.

O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ.

Int J Gynecol Cancer. 2016 Jul;26(6):1004-11. doi: 10.1097/IGC.0000000000000745.

PMID:
27327149
19.

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NJ, Jamieson D, Reeves HL.

J Hepatol. 2016 Aug;65(2):305-13. doi: 10.1016/j.jhep.2016.04.014. Epub 2016 Apr 27.

PMID:
27132171
20.

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Wang DD, Li C, Sun W, Zhang S, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):89-98. doi: 10.1002/cpdd.176. Epub 2015 Jan 26.

PMID:
27128213
21.

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.

Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ.

Int J Gynecol Cancer. 2016 May;26(4):763-9. doi: 10.1097/IGC.0000000000000654. Review.

PMID:
26905326
22.

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E.

Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287.

23.

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ.

Oncotarget. 2015 Oct 20;6(32):32396-409. doi: 10.18632/oncotarget.6136.

24.

mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.

Massey AJ, Stephens P, Rawlinson R, McGurk L, Plummer R, Curtin NJ.

Mol Oncol. 2016 Jan;10(1):101-12. doi: 10.1016/j.molonc.2015.08.004. Epub 2015 Aug 25.

25.

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.

Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, Moseley PM, Chan SY, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S.

Mol Oncol. 2016 Feb;10(2):213-23. doi: 10.1016/j.molonc.2015.09.009. Epub 2015 Oct 3.

26.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

27.

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.

Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FE, Jamieson D.

Int J Cancer. 2016 Jan 1;138(1):206-16. doi: 10.1002/ijc.29680. Epub 2015 Aug 19.

28.

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T.

PLoS One. 2015 Feb 17;10(2):e0118187. doi: 10.1371/journal.pone.0118187. eCollection 2015.

29.

PARP inhibitors target ATM+p53-defective gastric cancer.

Curtin NJ.

Cell Cycle. 2014;13(20):3161-2. doi: 10.4161/15384101.2014.948787. No abstract available.

30.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL.

Clin Cancer Res. 2015 Feb 15;21(4):925-33. doi: 10.1158/1078-0432.CCR-14-0842. Epub 2014 Dec 5.

31.

Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S.

Mol Oncol. 2015 Mar;9(3):569-85. doi: 10.1016/j.molonc.2014.10.013. Epub 2014 Nov 6.

32.

Development of pharmacodynamic biomarkers for ATR inhibitors.

Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ.

Mol Oncol. 2015 Feb;9(2):463-72. doi: 10.1016/j.molonc.2014.09.012. Epub 2014 Oct 13.

33.

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.

Znojek P, Willmore E, Curtin NJ.

Br J Cancer. 2014 Sep 23;111(7):1319-26. doi: 10.1038/bjc.2014.378. Epub 2014 Jul 8.

34.

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.

Patterson MJ, Sutton RE, Forrest I, Sharrock R, Lane M, Kaufmann A, O'Donnell R, Edmondson RJ, Wilson BT, Curtin NJ.

Br J Cancer. 2014 Jul 8;111(1):94-100. doi: 10.1038/bjc.2014.261. Epub 2014 May 27.

35.

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.

Vormoor B, Curtin NJ.

Curr Opin Oncol. 2014 Jul;26(4):428-33. doi: 10.1097/CCO.0000000000000091. Review.

36.

The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis.

O Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ.

PLoS One. 2014 Mar 6;9(6):e90604. doi: 10.1371/journal.pone.0090604. eCollection 2014.

37.

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.

Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ.

Br J Cancer. 2014 Apr 15;110(8):1977-84. doi: 10.1038/bjc.2014.91. Epub 2014 Feb 20.

38.

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.

Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ.

Breast Cancer Res Treat. 2014 Jan;143(1):47-55. doi: 10.1007/s10549-013-2785-6. Epub 2013 Nov 29.

PMID:
24292814
39.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

40.

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GC, Thommes P, Ting A, Griffin RJ.

J Med Chem. 2013 Aug 22;56(16):6386-401. doi: 10.1021/jm400915j. Epub 2013 Aug 1.

PMID:
23855836
41.

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Curtin NJ.

Br J Pharmacol. 2013 Aug;169(8):1745-65. doi: 10.1111/bph.12244. Review.

42.

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.

Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, Lau A, Newell DR, Curtin NJ.

Mol Cancer Ther. 2013 Jun;12(6):959-67. doi: 10.1158/1535-7163.MCT-12-0707. Epub 2013 Mar 19.

43.

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Curtin NJ, Szabo C.

Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29. Review.

44.

DNA repair dysregulation from cancer driver to therapeutic target.

Curtin NJ.

Nat Rev Cancer. 2012 Dec;12(12):801-17. doi: 10.1038/nrc3399. Review.

PMID:
23175119
45.

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ.

Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11.

46.

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.

Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear K, Slade A, Thommes P, Martin NM, Newell DR, Smith GC, Curtin NJ.

Mol Cancer Ther. 2012 Aug;11(8):1789-98. doi: 10.1158/1535-7163.MCT-11-0535. Epub 2012 May 10.

47.

Visualization of a DNA-PK/PARP1 complex.

Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH.

Nucleic Acids Res. 2012 May;40(9):4168-77. doi: 10.1093/nar/gkr1231. Epub 2012 Jan 5.

48.

Targeting the S and G2 checkpoint to treat cancer.

Chen T, Stephens PA, Middleton FK, Curtin NJ.

Drug Discov Today. 2012 Mar;17(5-6):194-202. doi: 10.1016/j.drudis.2011.12.009. Epub 2011 Dec 15. Review.

PMID:
22192883
49.

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

Javle M, Curtin NJ.

Ther Adv Med Oncol. 2011 Nov;3(6):257-67. doi: 10.1177/1758834011417039.

50.

The role of PARP in DNA repair and its therapeutic exploitation.

Javle M, Curtin NJ.

Br J Cancer. 2011 Oct 11;105(8):1114-22. doi: 10.1038/bjc.2011.382. Review.

Supplemental Content

Loading ...
Support Center